Transporting Therapeutics into The Brain

biOasis Technologies Inc. has developed and is now commercializing a ground-breaking platform for the delivery of therapeutic compounds across the blood-brain barrier and into the Central Nervous System for the treatment of neurological diseases, including, but not limited to, brain cancers, neurodegenerative and metabolic diseases. With the ability to transport therapeutics of almost any type and size across the blood-brain barrier, the Transcend Platform is now available to be licensed by biotechnology and pharmaceutical companies for the advancement of their neurotherapeutic programs.


The Transcend Platform

The Transcend Platform consists of a diverse suite of peptide carriers and linkers that together provide transport solutions for a host of CNS therapeutics including monoclonal antibodies, enzymes, small molecules and various types of gene therapies.

Designed to deliver high concentrations of therapeutics into the CNS with minimal dosing requirements and with no disruption of the blood-brain barrier, The Transcend Platform is based on Receptor Mediated Transcytosis, nature’s own method of carrying compounds into the brain. The Transcend Platform has achieved an exceptionally high success rate in the transport of dozens of compounds across the BBB in both in vitro and in vivo studies at over twenty third-party institutions and corporations. The studies illustrate that the Transcend Peptide does not materially affect either the half-life or efficacy of the transported therapeutics. Data from many of these studies are available for review by pharmaceutical and biotech corporations and institutions.

Licensing Opportunities

biOasis has developed flexible licensing models that allow pharmaceutical companies and biotechs to advance and commercialize their neurotherapeutic pipelines. The Transcend Platform’s comprehensive patent structure provides licensees with exceptional protection of their intellectual property and with the opportunity to further protect fusion proteins and conjugates developed within the terms of their biOasis Transcend Platform licenses.

When Transcend was conjugated with Trastuzumab it was shown in vivo to deliver Trastuzumab across the BBB and into the brain.

Antibodies directed at Aβ could offer therapeutic opportunities for reducing amyloid plaques in the brain for a potential treatment in Alzheimer’s disease.

Lysosomal storage diseases (“LSD”) are rare inherited metabolic diseases caused by a defective gene that result in an enzyme deficiency in lysosome cellular structures.

Small-Interfering RNA (siRNA) is a gene silencing technology which can be used to reduce the expression (commonly called a “knock-down”) of specific disease causing genes.